NCT05027243

Brief Summary

Temporomandibular joint (TMJ) arthroscopy has been used successfully for intra-articular disorders. Until now, limited studies are available regarding the clinical evidence of bilateral TMJ arthroscopy for Dimitroulis 2-3. This prospective study investigated the efficacy of TMJ arthroscopy in patients with bilateral disorders, and also the need for a posterior surgery.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2016

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2021

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

August 24, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 30, 2021

Completed
Last Updated

September 16, 2021

Status Verified

September 1, 2021

Enrollment Period

5.5 years

First QC Date

August 24, 2021

Last Update Submit

September 8, 2021

Conditions

Keywords

Temporomandibular jointTMJ arthroscopyTMJ surgery

Outcome Measures

Primary Outcomes (2)

  • Pain (Visual Analogue Scale (0,10)

    VAS, 0-10, with 0 being no pain and 10 having maximum unbearable pain

    Pre-surgery

  • Pain (Visual Analogue Scale (0,10)

    VAS, 0-10, with 0 being no pain and 10 having maximum unbearable pain

    Through study completion, an average of 2.5 years

Secondary Outcomes (4)

  • Maximum mouth opening (MMO, mm)

    Pre-surgery

  • Maximum mouth opening (MMO, mm)

    Through study completion, an average of 2.5 years

  • Muscle tenderness (0-3 scale)

    Pre-surgery

  • Muscle tenderness (0-3 scale)

    Through study completion, an average of 2.5 years

Study Arms (1)

bilateral temporomandibular joint arthroscopy

EXPERIMENTAL
Procedure: bilateral temporomandibular joint arthroscopyDrug: Xeomin® (Merz)

Interventions

The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.

bilateral temporomandibular joint arthroscopy

For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.

bilateral temporomandibular joint arthroscopy

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • age \>16 years;
  • clinical diagnosis of bilateral intra-articular disorder;
  • clinical criteria for bilateral TMJ arthroscopy;
  • magnetic resonance imaging (MRI) assessing the intra-articular derangement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

incobotulinumtoxinA

Study Officials

  • David Ângelo, MD, PhD

    Instituto Português da Face

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Prospective study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Director

Study Record Dates

First Submitted

August 24, 2021

First Posted

August 30, 2021

Study Start

January 2, 2016

Primary Completion

June 26, 2021

Study Completion

July 31, 2021

Last Updated

September 16, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share